Vaxcyte, Inc.

Vaxcyte is a clinical-stage biotechnology company focused on developing conjugate and protein vaccines for bacterial infectious diseases. The company's pipeline centers on pneumococcal conjugate vaccines (PCVs), with VAX-24 as its lead candidate—a 24-valent carrier-sparing PCV designed to prevent invasive pneumococcal disease in infants. The company also is advancing VAX-31, a 31-valent PCV for adults and children, which represents an expansion of the addressable market beyond pediatric populations.

Beyond pneumococcal vaccines, Vaxcyte is developing vaccines targeting other bacterial pathogens. VAX-A1 targets Group A Streptococcus, while VAX-PG is a protein vaccine candidate addressing periodontitis. The company also has preclinical and early-stage programs including VAX-GI for Shigella-caused dysentery and shigellosis, and VAX-XL, a third-generation pneumococcal conjugate vaccine.

The company operates as a private development-stage enterprise with no approved products on the market. Vaxcyte has 507 full-time employees and is headquartered in San Carlos, California. As of its incorporation in 2013 (following its May 2020 name change from SutroVax), the company remains focused entirely on vaccine development and has not yet generated product revenue.